Recombinant Complement Receptor 2 Radiolabeled with [Tc-99m(CO)(3)](+): A Potential New Radiopharmaceutical for Imaging Activated Complement

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)

Abstract

We describe the design and synthesis of a new Tc-99m labeled bioconjugate for imaging activated complement, based on Short Consensus Repeats 1 and 2 of Complement Receptor 2 (CR2), the binding domain for C3d. To avoid non specific modification of CR2 and the potential for modifying lysine residues critical to the CR2/C3d contact surface, we engineered a new protein, recombinant CR2 (rCR2), to include the C-terminal sequence VFPLECHHHHHH, a hexahistidine tag (for site-specific radiolabeling with [Tc-99m(CO)(3)(OH2)(3)](+)). The protein was characterized by N-terminal sequencing, SDS-PAGE and size exclusion chromatography. To test the function of the recombinant CR2, binding to C3d was confirmed by enzyme-linked immunosorbent assay (ELISA). The function was further confirmed by binding of rCR2 to C3d(+) red blood cells (RBC) which were generated by deposition of human or rat C3d and analyzed by fluorescence microscopy and flow cytometry. The affinity of rCR2 for C3d(+), in presence of 150 mM NaCl, was measured using surface plasma resonance giving rise to a K-D approximate to 500 nM. Radiolabeling of rCR2 or an inactive mutant of rCR2 (K41E CR2) or an unrelated protein of a similar size (C2A) with [Tc-99m(CO)(3)(OH2)(3)](+) at gave radiochemical yields >95%. Site-specifically radiolabeled rCR2 bound to C3d to C3d(+) RBC. Binding of radiolabeled rCR2 to C3d was inhibited by anti-C3d and the radiolabeled inactive mutant K41E CR2 and C2A did not bind to C3d(+) RBCs. We conclude that rCR2-Tc-99m has excellent radiolabeling, stability and C3d binding characteristics and warrants in vivo evaluation as an activated complement imaging agent.
Original languageEnglish
Article numbere18275
JournalPL o S One
Volume6
Issue number4
DOIs
Publication statusPublished - 2011

Fingerprint

Dive into the research topics of 'Recombinant Complement Receptor 2 Radiolabeled with [Tc-99m(CO)(3)](+): A Potential New Radiopharmaceutical for Imaging Activated Complement'. Together they form a unique fingerprint.

Cite this